Omeros announced positive results from its Phase 2b study of OMS302 for the maintenance of mydriasis and reduction of postoperative ocular pain in patients undergoing cataract surgery. The multicenter, randomized, double-blind, vehicle-controlled trial, conducted in 221 patients, demonstrated that OMS302 achieved statistically significant (p<0.0001) and clinically meaningful maintenance of mydriasis throughout the cataract procedure. OMS302 also significantly decreased pain (p=0.0418) in the early postoperative period and reduced the frequency of complaints of moderate and severe pain (2.5 times more complaints in the vehicle-treated patients).
OMS302 is a combination of an anti-inflammatory agent and an agent that causes mydriasis.
For more information call (206) 676-5000 or visit www.omeros.com.